© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert perspectives on the diagnosis and management of uncontrolled polycythemia vera in a 60-year-old man.
May 12th 2022
Expert Prithviraj Bose, MD, reviews standard practices in diagnosing and risk stratifying uncontrolled polycythemia vera in the context of a patient case.
A comprehensive review of the treatment armamentarium for polycythemia vera, as well as strategies to monitor patients on therapy in this setting.
Considerations for therapy when patients with polycythemia vera experience hydroxyurea resistance or intolerance.
In discussing the role of ruxolitinib in HU-resistant or intolerant PV, expert Prithviraj Bose, MD, highlights data from the RESPONSE and RESPONSE-2 clinical trials.
Expert perspectives on long-term management of patients with polycythemia vera, with regard for the risk of developing secondary MF or AML.
Description: Before closing out his discussion on polycythemia vera management, Prithviraj Bose, MD, shares excitement for emerging therapeutics in this setting.